Trademark Overview

---

On Friday, September 19, 2014, a trademark application was filed for CENTANAFADINE SR IS A NOREPINEPHRINE- AND DOPAMINE-PREFERRING TRIPLE REUPTAKE INHIBITOR THAT HAS THE RIGHT RATIO FOR THE RIGHT PATIENT with the United States Patent and Trademark Office. The USPTO has given the CENTANAFADINE SR IS A NOREPINEPHRINE- AND DOPAMINE-PREFERRING TRIPLE REUPTAKE INHIBITOR THAT HAS THE RIGHT RATIO FOR THE RIGHT PATIENT trademark a serial number of 86434375. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, July 9, 2018. This trademark is owned by NEUROVANCE, INC.. The CENTANAFADINE SR IS A NOREPINEPHRINE- AND DOPAMINE-PREFERRING TRIPLE REUPTAKE INHIBITOR THAT HAS THE RIGHT RATIO FOR THE RIGHT PATIENT trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for neurological use, Attention Deficit Hyperactivity Disorder, psychiatric diseases and disorders, all of which contain a compound that is a norepinephrine and dopamine-preferring triple reuptake inhibitor

General Information

---

Serial Number	86434375
Word Mark	CENTANAFADINE SR IS A NOREPINEPHRINE- AND DOPAMINE-PREFERRING TRIPLE REUPTAKE INHIBITOR THAT HAS THE RIGHT RATIO FOR THE RIGHT PATIENT
Filing Date	Friday, September 19, 2014
Status	606 - ABANDONED - NO STATEMENT OF USE FILED
Status Date	Monday, July 9, 2018
Registration Number	0000000
Registration Date	NOT AVAILABLE
Mark Drawing	4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition Date	Tuesday, April 7, 2015

Trademark Statements

---

Goods and Services

Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for neurological use, Attention Deficit Hyperactivity Disorder, psychiatric diseases and disorders, all of which contain a compound that is a norepinephrine and dopamine-preferring triple reuptake inhibitor

Classification Information

---

International Class	005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes	006, 018, 044, 046, 051, 052
Class Status Code	6 - Active
Class Status Date	Tuesday, November 4, 2014
Primary Code	005
First Use Anywhere Date	NOT AVAILABLE
First Use In Commerce Date	NOT AVAILABLE

Trademark Owner History

---

Party Name	NEUROVANCE, INC.
Party Type	20 - Owner at Publication
Legal Entity Type	03 - Corporation
Address	Princeton, MA 08540

---

Party Name	NEUROVANCE, INC.
Party Type	10 - Original Applicant
Legal Entity Type	03 - Corporation
Address	Cambridge, MA 02141

Trademark Events

---

Event Date	Event Description
Monday, July 9, 2018	ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, July 9, 2018	ABANDONMENT - NO USE STATEMENT FILED
Friday, December 8, 2017	NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 7, 2017	EXTENSION 5 GRANTED
Friday, December 1, 2017	EXTENSION 5 FILED
Thursday, December 7, 2017	CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, December 1, 2017	TEAS EXTENSION RECEIVED
Tuesday, June 6, 2017	NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, June 2, 2017	EXTENSION 4 GRANTED
Friday, June 2, 2017	EXTENSION 4 FILED
Friday, June 2, 2017	TEAS EXTENSION RECEIVED
Tuesday, December 20, 2016	NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 19, 2016	EXTENSION 3 GRANTED
Friday, December 2, 2016	EXTENSION 3 FILED
Friday, December 2, 2016	TEAS EXTENSION RECEIVED
Saturday, July 9, 2016	NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, July 8, 2016	EXTENSION 2 GRANTED
Thursday, June 2, 2016	EXTENSION 2 FILED
Tuesday, July 5, 2016	CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, June 27, 2016	ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, June 27, 2016	TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, June 2, 2016	TEAS EXTENSION RECEIVED
Thursday, June 2, 2016	TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, December 4, 2015	NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 2, 2015	EXTENSION 1 GRANTED
Wednesday, December 2, 2015	EXTENSION 1 FILED
Wednesday, December 2, 2015	TEAS EXTENSION RECEIVED
Tuesday, June 2, 2015	NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 7, 2015	OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 7, 2015	PUBLISHED FOR OPPOSITION
Wednesday, March 18, 2015	NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 3, 2015	LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, March 3, 2015	ASSIGNED TO LIE
Wednesday, February 11, 2015	APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 11, 2015	EXAMINER'S AMENDMENT ENTERED
Wednesday, February 11, 2015	NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, February 11, 2015	EXAMINERS AMENDMENT E-MAILED
Wednesday, February 11, 2015	EXAMINERS AMENDMENT -WRITTEN
Friday, February 6, 2015	PREVIOUS ALLOWANCE COUNT WITHDRAWN
Tuesday, January 27, 2015	WITHDRAWN FROM PUB - OG REVIEW QUERY
Tuesday, January 6, 2015	APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, January 5, 2015	ASSIGNED TO EXAMINER
Monday, November 17, 2014	REQUEST TO CORRECT FILING DATE - GRANTED
Monday, November 17, 2014	ASSIGNED TO PETITION STAFF
Tuesday, November 4, 2014	NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, October 24, 2014	REQUEST TO CORRECT FILING DATE RECEIVED
Tuesday, October 28, 2014	NEW APPLICATION ENTERED IN TRAM
Friday, October 24, 2014	FAX RECEIVED

Related Keywords

---

right inhibitor ratio patient reuptake triple norepinephrine dopamine preferring centanafadine preparations pharmaceutical contain which disorders compound diseases